FibroBiologics, Inc. Common Stock (FBLG)
Automate Your Wheel Strategy on FBLG
With Tiblio's Option Bot, you can configure your own wheel strategy including FBLG - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol FBLG
- Rev/Share 0.0
- Book/Share 0.0641
- PB 11.2048
- Debt/Equity 0.5434
- CurrentRatio 1.1359
- ROIC -4.0857
- MktCap 27472536.0
- FreeCF/Share -0.3578
- PFCF -2.0939
- PE -3.4344
- Debt/Assets 0.1118
- DivYield 0
- ROE -5.6427
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | FBLG | Rodman & Renshaw | -- | Buy | -- | $12 | Dec. 12, 2024 |
| Initiation | FBLG | Maxim Group | -- | Buy | -- | $12 | Sept. 24, 2024 |
News
FibroBiologics to Present at the BIO International Convention 2025
Published: June 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O'Heeron, will present a company update at the BIO International Convention 2025, June 16-19, 2025, in Boston, MA. The presentation will include recent corporate milestones and research advances using fibroblast-based technology for indications such as wound healing, multiple sclerosis, and psoriasis.
Read More
FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
HOUSTON, May 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Senior Research Scientist, Dr. Chuo Fang M.D., Ph.D., delivered a poster presentation at the Society for Investigative Dermatology (SID) Annual Meeting that took place in San Diego May 7-10, 2025. The SID Annual Meeting provides a premier forum for skin biology research and education for researchers to share transformative scientific discoveries and medical innovations that improve …
Read More
FibroBiologics Presenting at the ThymUS 2025 Meeting
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Simon Gebremeskel, research scientist at FibroBiologics, is presenting a poster at the ThymUS 2025 Meeting taking place in Lihue, Kaua'i Hawaii from April 27 - May 1, 2025. Founded in 2001, ThymUS brings together international researchers working on thymus and T-cell biology.
Read More
FibroBiologics Presents at the ThymUS 2025 Meeting
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Simon Gebremeskel, research scientist at FibroBiologics, is presenting a poster at the ThymUS 2025 Meeting taking place in Lihue, Kaua'i Hawaii from April 27 - May 1, 2025. Founded in 2001, ThymUS brings together international researchers working on thymus and T-cell biology.
Read More
About FibroBiologics, Inc. Common Stock (FBLG)
- IPO Date 2024-02-01
- Website https://www.fibrobiologics.com
- Industry Biotechnology
- CEO Mr. Peter O'Heeron
- Employees 13